Taking on board COVID-19 vaccine approval euphoria plus growth prospects
30/12/20 -"With UK’s emergency use approval for Astra-Oxford’s COVID-19 vaccine candidate, the sentiment around Astra’s share price should improve finally. Besides taking on board the 100% probability of ..."
Pages
66
Language
English
Published on
30/12/20
You may also be interested by these reports :
26/02/26
Even though the H2 25 results were ahead of consensus, the 2026 outlook was below the street’s expectations. While Branded posted strong H2 growth, ...
26/02/26
Novonesis stumbled at the finish line — Q4 25 revenue and EBITDA missed consensus by 2.3% and 2.9% respectively, dragged down by weakness in the ...
26/02/26
The H2 25 results exceeded the consensus, and the 2026 guidance (CER) was better than the consensus estimates at AER. The H2 performance was driven ...
25/02/26
While Q4 sales met the street’s expectations, H2 25 profitability somewhat exceeded the consensus. Most of the Q4 growth was driven by strong demand ...